Generating and expanding autologous chimeric antigen receptor T cells from patients with acute myeloid leukemia

Saad Kenderian, Carl H. June, Saar Gill

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

Adoptive transfer of genetically engineered T cells can lead to profound and durable responses in patients with hematologic malignancies, generating enormous enthusiasm among scientists, clinicians, patients, and biotechnology companies. The success of adoptive cellular immunotherapy depends upon the ability to manufacture good quality T cells. We discuss here the methodologies and reagents that are used to generate T cells for the preclinical study of chimeric antigen receptor T cell therapy for acute myeloid leukemia (AML).

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages267-276
Number of pages10
DOIs
StatePublished - Jan 1 2017

Publication series

NameMethods in Molecular Biology
Volume1633
ISSN (Print)1064-3745

    Fingerprint

Keywords

  • Acute myeloid leukemia
  • Adoptive T cell therapy
  • CAR T cells
  • Chimeric antigen receptor
  • Synthetic biology
  • T cell expansion

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Kenderian, S., June, C. H., & Gill, S. (2017). Generating and expanding autologous chimeric antigen receptor T cells from patients with acute myeloid leukemia. In Methods in Molecular Biology (pp. 267-276). (Methods in Molecular Biology; Vol. 1633). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7142-8_17